


Curriculum Vitae

Name	Inkeun Park	
Current Position & Affiliation	Associate Professor Gachon University Gil Medical Center, Department of Internal Medicine, Division of Medical Oncology	
Country	Republic of Korea	

Educational Background

Degree-granting education

2000-2004 Kyunghee University College of Medicine, MD

2007-2009 University of Ulsan College of Medicine, MSc

2013-2017 University of Ulsan College of Medicine, PhD

Postgraduate training

2005-2009 Resident, Internal Medicine, Asan Medical Center

2012-2013 Fellowship, Medical Oncology, Asan Medical Center

2013-2014 Fellowship, Medical Oncology, Gil Medical Center

Professional Experience

2014-2020 Assistant Professor, Medical Oncology, Gil Medical Center

2020- Associate Professor, Medical Oncology, Gil Medical Center

Professional Organizations

Member, Korean Medical Association

Member, Korean Association of Internal Medicine

Member, Korean Society of Medical Oncology

Member, Korean Cancer Association

Member, Korean Cancer Study Group

Special Member, Korean Urological Oncology Society

Main Scientific Publications

1. Seo JY, Ahn JY, Keam B, Kim M, Yoon S, Lee JL, Park K, Park I. Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell cancer syndrome in Korean patients. *Ann Lab Med*. 2021;41:207-213
2. Park I, Lee JL. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. *Korean J Intern Med* 2020;35:834-853
3. Park I, Kim BS, Lim HY, Kim HJ, Lee HJ, Choi YJ, Park KH, Lee KH, Yoon S, Hong B, Hong JH, Ahn H, Lee JL: Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU 10-16). *Eur J Cancer* 2020;127:183-190
4. Park I, Lee HJ, Bae WK, Yoon S, Lee JL: A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component. *Invest New Drugs* 2019;37:1239-1246
5. Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi YJ, Seo JY, Park I, Lee JL: Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: A multicenter retrospective analysis in Korean patients. *Cancer Res Treat* 2019;51:1549-1556
6. Ansari AA, Park I, Kim I, Park S, Ahn SM, Lee JL: Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer. *BMC Med Genomics* 2018;11:88
7. Park I, Lee SH, and Lee JL: A multicenter phase II trial of axitinib in patients with recurrent or metastatic non-clear cell renal cell carcinoma who had failed prior treatment with temsirolimus. *Clin Genitourin Cancer* 2018;16:e997-e1002
8. Park I, Cho YM, Lee JL, Ahn JH, Lee DH: Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. *Tumour Biol* 2016;37:4919-27